The Swiss drugmaker is licensing an investigational obesity candidate from the Chinese biotech, Reuters reports.
Recap by typeshit. Full story at Reuters on MSN.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
A Minutes of Health clip, in English and Arabic, walks through what the GLP-1 hormone does and how popular treatments use it.
The Phase III trial tested Lilly's once-weekly triple receptor agonist for efficacy and safety in people with obesity and type 2 diabetes.
Loading…